Fundraising Fox

NextPoint Therapeutics

Austin, US · Delaware corporation · 5 known investors

nextpointtx.com ↗

NextPoint is developing precision cancer therapeutics based on the B7-H7/HHLA2 axis, including T-cell engagers, antibody-drug conjugates, and checkpoint inhibitors for cancer patients. The company focuses on immuno-oncology and tumor-targeting therapies.

BiotechDigital HealthMedical Devicesin /nextpoint-therapeutics@NextPointTX

Founders & leadership

DB
Detlev BiniszkiewiczDirector
IC
Ivan CheungExecutive Officer, Director
AH
Axel HoosDirector
RJ
R. Jacob VogelsteinDirector
BS
Brian ShusterDirector
PH
Paulina HillDirector
RD
Rakhshita DharDirector
JL
Jeffrey LaceyExecutive Officer

Investors · 5

Catalio Capital Management, LPNew York
MPM BioImpactBoston · $1M – $15M
MPM Capitalvia Ansbert Gadicke · board
Sanofi VenturesCambridge · $5M
Leaps by BayerreportedLeverkusen

Reported raises · per SEC filings

Form D private placements
▶$33.7MraisedJul 2026 · 15 investors · Biotechnology
Rule 506(b)
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells | Nature Biotechnologynature.com · Jul 2026
Officers, directors & promoters on the filing
  • Detlev BiniszkiewiczDirector
  • Ivan CheungExecutive Officer, Director
  • Axel HoosDirector
  • R. Jacob VogelsteinDirector
  • Brian ShusterDirector
  • Paulina HillDirector
  • Rakhshita DharDirector
  • Jeffrey LaceyExecutive Officer
Offering amount
$48.7M
Amount sold
$33.7M
Proceeds to insiders
$2.5M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.5MraisedFeb 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew Roden)Director
  • Axel HoosDirector
  • Paulina HillDirector
  • Ivan CheungExecutive Officer, Director
  • Detlev BiniszkiewiczDirector
  • Rakhshita DharDirector
  • Paul ConradExecutive Officer
  • R. Jacob VogelsteinDirector
Offering amount
$42.5M
Amount sold
$42.5M
Proceeds to insiders
$1.3M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedDec 2022 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paulina HillDirector
  • Detlev BiniszkiewiczExecutive Officer, Director
  • Paul ConradExecutive Officer
  • Matthew RodenDirector
  • Rakhshita DharDirector
  • Ansbert GadickeDirector
Offering amount
$80M
Amount sold
$80M
Proceeds to insiders
$1.7M
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news